メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
加藤 卓
医学部・臨床検査科・第１
h-index
1264
被引用数
20
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2005
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(62)
類似のプロファイル
(6)
フィンガープリント
Taku Katoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Neoplasm
55%
Prostate Cancer
35%
Cancer Cell
27%
Cancer
23%
Kidney Transplantation
23%
in Situ Hybridization
22%
Bladder Cancer
20%
Penile Cancer
20%
Bladder
20%
Kidney Graft
20%
Malignant Neoplasm
18%
Computer Assisted Tomography
15%
Angioleiomyoma
12%
Recurrent Disease
12%
Kidney Injury
12%
Diagnosis
11%
Gemcitabine
11%
Prostate Biopsy
11%
Escherichia coli
11%
Magnetic Resonance Imaging
11%
Urinary Tract Infection
10%
Receptor
10%
Acute Heart Infarction
10%
Solitary Fibrous Tumor
10%
Pembrolizumab
10%
Retrospective Study
10%
Enzalutamide
10%
Prostate Specific Membrane Antigen
10%
Expression Vector
10%
Formaldehyde
10%
Ureterocele
10%
microRNA
10%
Granulocyte Colony Stimulating Factor
10%
Low Drug Dose
10%
Chlormadinone Acetate
10%
Gene Translocation
10%
Dedifferentiated Liposarcoma
10%
Prostate Specific Antigen
10%
Kidney Metastasis
10%
Plasma Cell Granuloma
10%
Androgen Receptor
10%
Long Untranslated RNA
10%
Promoter Region
10%
Gene Therapy
10%
Targeted Therapy
10%
Perforin
10%
Secretion (Process)
10%
Urinoma
10%
Brachytherapy
10%
Wart Virus
10%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
microRNA
41%
Androgen Receptor
31%
Docetaxel
29%
Taxane
24%
Renal Cell Carcinoma
24%
Kidney Metastasis
20%
Paclitaxel
20%
Malignant Neoplasm
19%
Cabazitaxel
15%
Drug Resistance
13%
Cancer Growth
12%
P-Glycoprotein
11%
Castration Resistant Prostate Cancer
11%
Kavalactones
10%
Sunitinib
10%
Urinary Tract Infection
10%
Penis Cancer
10%
Cytochrome P450 1A1
10%
Acute Heart Infarction
10%
Retrospective Study
10%
Mouth Cancer
10%
Catenin
10%
Bladder Cancer
10%
Ureterocele
10%
Chlormadinone Acetate
10%
Infection
10%
Receptor
10%
Axitinib
10%
Caspase 8
10%
Taxoid
10%
Sorafenib
10%
Cytokine
10%
Gelatinase A
10%
Gemcitabine
10%
Enzalutamide
10%
Messenger RNA
10%
Tubulin
8%
Levofloxacin
7%
Escherichia coli
7%
Multidrug Resistance Protein 1
7%
Glycoprotein
6%
Gelatinase B
6%
Small Interfering RNA
5%
Xenobiotic Agent
5%
Extended Spectrum Beta Lactamase
5%
Adverse Event
5%
Western Blot
5%
Keyphrases
Prostate Cancer Cells
24%
Taxanes
22%
MicroRNA
20%
Paclitaxel-resistant
17%
Prostate Cancer Patients
12%
Matrix metalloproteinase-9 (MMP-9)
12%
Resistant Prostate Cancer
12%
Diagnostic Marker
11%
Human Prostate Cancer Cells
11%
Therapeutic Evaluation
10%
Nrf2 Signaling
10%
Kavalactones
10%
Advanced Renal Cell Carcinoma
10%
Receptor 1
10%
Bilateral Renal Cell Carcinoma
10%
Potential Biomarkers
10%
SpaceOAR Hydrogel
10%
Multiple Metastases
10%
Spontaneous Healing
10%
Ureterocele
10%
Docetaxel Resistance
10%
Anchorage-independent Aggregation
10%
SAS Cell
10%
MiRNA-93
10%
Chlormadinone Acetate
10%
Clinical Analysis
10%
Prostate Cancer Relapse
10%
Cardiac Metastasis
10%
Combined Modality Therapy
10%
Serum Exosomes
10%
MiR-24
10%
General Pathologist
10%
Gemcitabine-resistant
10%
Chemoresistance
10%
Apoptotic Pathway
10%
Caspase-8
10%
Penile Cancer
10%
Clear Cell Renal Cell Carcinoma (ccRCC)
10%
MiR-34b
10%
Matrix metalloproteinase-2 (MMP-2)
10%
Prostate Cancer Aggressiveness
10%
CD44v8-10
10%
CYP1A1 Gene
10%
Hormone Refractory
10%
Extracellular Vesicles
10%
Kartogenin
10%
Chromogenic in Situ Hybridization
10%
Rectal Hemorrhage
10%
Post-transplant Diabetes Mellitus
10%
Blunt Renal Trauma
10%
